Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928787 | 0.82 | PIK3C3 (0.38) | PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA | |
| SCHEMBL9954073 | 0.78 | PIK3CG (0.36) | PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA | |
| SCHEMBL9953793 | 0.76 | PIK3CG (0.39) | PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA | |
| SCHEMBL12813030 | 0.74 | PIK3CD (0.49) | PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA | |
| SCHEMBL29688377 | 0.73 | KCNQ3 (0.37) | PIK3CD | |
| SCHEMBL20254620 | 0.73 | KCNQ3 (0.37) | PIK3CD | |
| SCHEMBL12813245 | 0.72 | PIK3CD (0.38) | PIK3C3PIK3CGPIK3CBPIK3CDPIK3CA | |
| SCHEMBL20254736 | 0.71 | PTGES (0.40) | PIK3CAPI4KB | |
| SCHEMBL29689135 | 0.71 | PTGES (0.40) | PIK3CAPI4KB | |
| SCHEMBL19571043 | 0.67 | PIK3CD (0.39) | PIK3C3PIK3CGPIK3CBPIK3CDGPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660016-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-2655374-B1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9815839-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170158696-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-9527848-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-9096600-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | PIK3C3 80/4885PIK3CG 5/4885PIK3CB 4/4885 |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | PIK3C3 80/4885PIK3CG 5/4885PIK3CB 4/4885 |
| US-20170158696-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | PIK3C3 80/4885PIK3CG 5/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.